Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings by Rose, Tracy L. et al.
Neoadjuvant chemotherapy administration and time to 
cystectomy for muscle-invasive bladder cancer: An evaluation of 
transitions between academic and community settings
Tracy L. Rose, M.D., M.P.H.a, Allison M. Deal, M.S.b, Ethan Basch, M.D., M.Sc.a, Paul A. 
Godley, M.D., Ph.D.a, W. Kimryn Rathmell, M.D., Ph.D.a, William Y. Kim, M.D.a, Young E. 
Whang, M.D., Ph.D.a, Mary W. Dunn, N.P.c, Andrew Wang, M.D.d, Ronald C. Chen, M.D., 
M.P.H.d, Matthew E. Nielsen, M.D., M.S.c, Raj S. Pruthi, M.D.c, Eric M. Wallen, M.D.c, Michael 
E. Woods, M.D.c, Angela B. Smith, M.D.c, and Matthew I. Milowsky, M.D.a,*
aDepartment of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, 
Chapel Hill, NC
bBiostatistics and Clinical Data Management Core, University of North Carolina Lineberger 
Comprehensive Cancer Center, Chapel Hill, NC
cUrologic Oncology Program, Department of Urology, University of North Carolina Lineberger 
Comprehensive Cancer Center, Chapel Hill, NC
dDepartment of Radiation Oncology, University of North Carolina Lineberger Comprehensive 
Cancer Center, Chapel Hill, NC
Abstract
Objectives—Neoadjuvant chemotherapy (NAC) before radical cystectomy is the standard of care 
for muscle-invasive bladder cancer (MIBC). Many patients are referred to an academic medical 
center (AMC) for cystectomy but receive NAC in the community setting. This study examines if 
administration of NAC in the community is associated with differences in type of NAC received, 
pathologic response rate (pT0), and time to cystectomy as compared to NAC administered at an 
AMC.
Methods—We performed a retrospective study of patients with MIBC (cT2a-T4-Nx-M0) 
referred to a single AMC between 1/2012 and 1/2014 who received NAC. We analyzed 
chemotherapy received, time to cystectomy, pT0, and survival in patients who received NAC in 
our AMC compared to those treated in the community.
Results—In all, 47 patients were analyzed. A similar total dose of cisplatin (median: 280 mg/m2 
for both groups, P =0.82) and pT0 rate (25% vs. 29%, P =0.72) were seen in patients treated in our 
AMC and the community. However, administration of NAC in the community was associated with 
a prolonged time to cystectomy compared with that in our AMC (median number of days 162 vs. 
128, P < 0.01). This remained significant after adjusting for stage, comorbidity status, and distance 
to the AMC (P =0.02). Disease-free survival and overall survival did not differ.
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Conclusion—Patients with MIBC treated with NAC in the community as compared to an AMC 
received similar chemotherapy and achieved comparable pT0 rates, indicating effective 
implementation of NAC in the community. However, NAC in the community was associated with 
longer time to cystectomy, suggesting a delay in the transition of care between settings.
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1. Introduction
Bladder cancer is the 6th most common cancer in the United States, with an estimated 
74,690 new cases and 15,580 deaths for 2014 [1]. Although most cases are noninvasive at 
initial diagnosis, nearly 25% of these cases progress to muscle-invasive bladder cancer 
(MIBC) and 20% to 30% of patients have MIBC at the time of diagnosis [2].
Treatment of MIBC requires coordinated multidisciplinary care that often stretches across 
practice settings. Neoadjuvant chemotherapy (NAC) before radical cystectomy represents a 
standard of care for MIBC based on randomized clinical trials and a meta-analysis [3–5]. 
The gradual but steady increase in implementation of NAC over the last 15 years has made 
transitions in care more common and important [6]. Many patients are referred to an 
academic medical center (AMC) upon diagnosis of MIBC for consideration of cystectomy 
because many community urologists do not routinely perform cystectomies, and centers with 
high surgical volume have improved perioperative mortality and long-term mortality rates 
[7–9]. Many of these patients return to community oncologists for NAC before cystectomy, 
with others receiving NAC at the AMC in which they undergo surgery.
Treatment of patients with MIBC at different centers raises a potential issue of treatment 
coordination and delays [10,11]. A treatment delay of more than 3 months from initial 
diagnosis to cystectomy has been associated with decreased overall survival (OS) in several 
studies of patients who did not receive NAC [12,13]. There is also an association of a 
treatment delay with worse pathologic stage at the time of cystectomy [12–19]. An 
association of delay with adverse outcomes in patients receiving NAC, however, is less well 
studied.
It is not known if patients who are referred to the community setting for NAC have a delay 
in cystectomy compared with patients who remain at the referral AMC for NAC. It is also 
not known if delay to cystectomy is associated with a decrease in survival or pathologic 
response rate (pT0) in patients who receive NAC in these different settings. The goals of this 
retrospective study are to examine time to cystectomy, chemotherapy received, pT0, and 
survival in patients who receive NAC before cystectomy in the community setting compared 
to an AMC.
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2. Materials and methods
2.1. Study population
We performed a retrospective chart review at a single academic institution using the 
University of North Carolina Genitourinary OncoLogy Database (UNC GOLD) [20], a 
clinical database that captures all patients seen in the UNC multidisciplinary genitourinary 
oncology clinic. This study was approved by the Institutional Review Board at UNC.
A query of UNC GOLD for all MIBC (T2-T4-Nx-M0) cases between January 1, 2012 and 
January 2, 2014 revealed 94 patients recommended to undergo cystectomy at their initial 
visit after diagnosis. A medical record chart review of these patients revealed that 47 of 94 
patients (50%) received NAC—these patients formed our study cohort. Of those who did not 
receive NAC, the most common reasons included renal dysfunction (26%), patient 
preference (21%), and hearing loss (14%).
2.2. Study variables
Data collected included patient demographics, stage, comorbidity score, site of NAC 
delivery (i.e., AMC or community), chemotherapeutic regimen, time to cystectomy, 
pathologic response rate, disease-free survival (DFS), and OS. Time to cystectomy was 
calculated from the day of initial consultation with medical oncology at our institution to the 
day of cystectomy. Stage was determined by American Joint Committee on Cancer TNM 
stage recorded before NAC (clinical stage) and after cystectomy (pathologic stage). 
Comorbidity score was calculated using age-adjusted Charlson Comorbidity index score 
[21]. Distance to the AMC was calculated from the site of each patient’s residence to our 
institution. The date of cessation of NAC was defined as the last date the patient received 
any chemotherapy. The NAC regimen for each patient was recommended by the medical 
oncologist at our AMC for all patients. Pathologic response rate was defined as pT0 (pT0-
N0-M0) at the time of cystectomy. Rate of <pT2 (pT0-T1-N0-M0) at the time of cystectomy 
was also examined. Patients with available data were evaluated for bladder cancer 
progression/recurrence and survival.
The primary exposure variable was whether NAC was given at AMC or a community 
oncology practice. The primary outcome was time to cystectomy from date of initial visit at 
AMC. Secondary outcomes were pathologic response rate and total dose of cisplatin 
received with NAC, DFS, and OS.
2.3. Statistical analysis
Descriptive statistics were obtained for continuous and categorical variables. Means and 
standard deviation were used for continuous variables and frequencies for categorical 
variables. Fisher’s exact tests were used to compare categorical variables and Wilcoxon rank 
sums were used for continuous variables. Multivariable linear regression was used for the 
model with outcome of time to cystectomy in days. Cox proportional hazards analysis was 
used for DFS and OS calculations. All statistical analysis was conducted using SAS software 
(SAS Institute Inc., Cary, NC) and a P < 0.05 was considered statistically significant.
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In all, 47 patients received NAC. Of these, 31 patients (66%) received NAC in the 
community and 16 (34%) received NAC at our AMC. Of the patients treated at our AMC, 3 
received NAC as part of a clinical trial. Demographic variables are listed in Table 1 and were 
similar between those who received NAC at our AMC and those treated in the community. 
Patients treated with NAC in the community lived at a greater distance from our AMC than 
those treated at our institution (130 vs. 58 miles, P =0.0003).
All but 1 patient received cisplatin-based combination chemotherapy and the regimen of 
gemcitabine and cisplatin (GC) was the most commonly administered (85% of patients 
received GC with most of them using every 3 wk dosing intervals). The median total dose of 
cisplatin received during NAC was 280 mg/m2 in both groups with no difference in dose 
between those who were treated at our AMC and those treated in the community (P =0.83). 
The median number of cycles was 4 in both groups with no statistical difference between 
groups (P =0.09). The single patient who received carboplatin instead of cisplatin was 
treated in the community. The median number of days between starting and ending NAC 
was not different between the 2 groups (P =0.33).
Of the original 47 patients, 38 underwent cystectomy at our AMC and had pathology 
available for review. One patient underwent cystectomy at an outside institution and 
pathology results were not available. Because of progression of disease during NAC (4 
patients), patient preference (3 patients), and death unrelated to NAC (1 patient), 8 patients 
did not undergo cystectomy. Of the patients who received NAC in the community, 81% 
eventually underwent cystectomy compared with 88% of patients at our AMC.
The median number of days between the initial visit with medical oncology at our AMC and 
cystectomy was significantly longer in the patients who were referred to the community 
setting for NAC than those who received NAC at our AMC (162 vs. 128 d, P =0.006). The 
median number of days between diagnostic TURBT and cystectomy was also significantly 
longer if NAC was given in the community setting (189 vs. 151 d, P =0.015). After 
controlling for stage at diagnosis, comorbidity score, and distance to the AMC, those who 
received NAC at our AMC had their cystectomy an average of 43 days earlier (P =0.015). 
Increasing stage and comorbidity score were associated with longer time to cystectomy on 
univariable analysis, although this association was not statistically significant in the 
multivariable model (P =0.14 and P =0.26, respectively). Distance to the AMC was not 
associated with time to cystectomy (P =0.63). In all, 6 patients had a delay of longer than 6 
months between initial visit and cystectomy. Of these, 5 had NAC administered in the 
community. Delays were due to scheduling issues (4 patients) and complications (1 
myocardial infarction requiring CABG, and 1 cerebral vascular event). The numbers of days 
of delay in each step of the treatment process are reported in Table 2. The time from initial 
visit with medical oncology to starting NAC was significantly longer in the group treated in 
the community (P =0.002) but the delay in other steps of the process did not independently 
reach significance.
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Of the patients who received NAC at our AMC, 50% had <pT2 and 29% had pT0 at the time 
of cystectomy. Of the patients who received NAC in the community, 50% had <pT2 and 
25% had pT0 at time of cystectomy (Table 3). There was no difference in pathologic 
response rate between the groups (P =1.0 and P =0.81 for <pT2 and pT0, respectively).
Of those patients who received NAC at our AMC and in the community, 4 (25%) and 3 
(10%) are known to have passed away at the last follow-up, respectively. Median OS was not 
reached in either group and the difference in OS was not statistically significant (P =0.20) 
(Fig. 1). DFS was also not different between the groups (P =0.50). Survival analyses 
included the patients who did not undergo cystectomy in addition to those who did. Median 
follow-up was 9.7 months in the group that received NAC at our institution and 6.7 months 
in the group that received NAC in the community.
4. Discussion
The current study demonstrated that time to cystectomy is delayed in patients with MIBC 
who were referred to the community setting to receive NAC compared with those who 
received it at an AMC. However, patients in the community and AMC received similar 
chemotherapy regimens and dosing, and there was no difference in pathologic response rate 
(including pT0), DFS, or OS.
When each step in the process of NAC administration was examined, the only significant 
time difference between those who received NAC at our institution and in the community 
was the delay between initial visit with medical oncology at our AMC and date of starting 
chemotherapy. This suggests that the delay to cystectomy is related to poor transitions of 
care between the AMC and community setting, as opposed to differences in the 
administration of chemotherapy or complications during treatment. This is supported by our 
findings that the total dose of cisplatin, number of cycles, and chemotherapy regimens 
administered were not different between the 2 groups, suggesting that the implementation 
and administration of NAC in the community setting was effective and similar to that in the 
academic setting. Lee et al. [13] have also suggested that delay to cystectomy is commonly 
due to avoidable issues such as scheduling and not due to patient-derived factors. It should 
be noted that the duration of chemotherapy (median: 64–68 d) would be the expected value 
for patients receiving 4 cycles of GC NAC because the date of cessation of NAC was defined 
as that of the last dose of chemotherapy administered. There was a delay of more than 30 
days in both groups between the urology visit after cessation of NAC and cystectomy, 
suggesting that delays in scheduling of cystectomy may contribute to the time to cystectomy 
in all patients. Although the patients who received NAC in the community lived a greater 
distance from our AMC, the difference in time to cystectomy between the 2 groups 
remained significant even after adjusting for distance, further suggesting that the transition 
of care between healthcare settings was driving the delay.
Our study is in agreement with a recent analysis by Tomaszewski et al. [10] using the 
National Cancer DataBase showing that patients with MIBC who changed hospitals between 
diagnosis and definitive therapy (which included NAC or radical cystectomy) were more 
likely to experience a treatment delay of 3 months or longer. In that study, care transitions 
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were associated with black race, male gender, Medicare or no insurance status, and 
treatment at an AMC. Our study did not find that such certain subgroups were more likely to 
have NAC at an outside facility, although it was not powered for such conclusions. Our study 
adds the knowledge that although a change in institution during treatment is associated with 
a delay, the actual chemotherapy regimens and dosages are consistent across settings.
Alva et al. [22] conducted a single-institution retrospective review and found that 
administration of NAC at an outside facility did not delay time between NAC completion 
and cystectomy. However, they did note that scheduling issues occurred disproportionately 
in the group of patients who received NAC outside their institution, suggesting the need for 
improved communication in care transitions. Our study suggested that a large portion of the 
delay experienced by patients treated at an outside facility may occur before initiating NAC, 
which was not examined in the Alva study.
The clinical relevance of a 43-day delay in cystectomy in patients who received NAC at an 
outside facility is not clear. The median number of days from initial visit to cystectomy at 
our AMC was 128, which is in keeping with the observed time from randomization to 
cystectomy in trials of NAC [3]. We found that pathologic response rate, DFS, and OS were 
not different depending on the site of NAC administration, suggesting that the observed 
delay did not translate to observable clinical significance. Our sample size may not be large 
enough to see an effect of delay to cystectomy on pathologic response rate and survival 
although Alva et al. [22] similarly did not see an association between time to cystectomy 
after NAC termination and survival. However, there are several studies demonstrating an 
association between inferior OS and delay to cystectomy of more than 12 weeks and OS 
appears to start decreasing at approximately 40 days after diagnosis in patients who do not 
receive NAC [12,14,15,23]. The acceptable time of delay to cystectomy remains unclear in 
patients undergoing NAC.
A limitation of this retrospective chart review is that we cannot be certain that patients 
treated with NAC at our AMC are the same as those treated at a community site, introducing 
the potential for unmeasured confounders. For example, although we had insurance 
information, we were unable to fully account for socioeconomic status in our analysis. In a 
study of breast cancer, several socioeconomic factors such as lack of insurance and low 
education were associated with increased time to surgery after diagnosis and increased time 
to adjuvant chemotherapy after surgery [24]. Another major limitation in our study is the 
limited follow-up data due to the fact that many patients received postcystectomy care at an 
outside facility. Our survival analysis is therefore limited.
Despite these limitations, we believe our institution is representative of a typical AMC. Our 
pathologic response rates are in keeping with observed rates in clinical trials of NAC (pT0 
was 32.5% in a large randomized trial, 28.5% in a meta-analysis of 13 trials, and 26.3% in 
our study) [3]. In addition, 50% of patients with MIBC in our study received NAC, which is 
well above the national average [6].
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Overall, the current study demonstrates a delay in time to cystectomy when NAC is 
administered in the community as compared with an AMC without a clear association with 
adverse outcomes. Transitions of care appear to be responsible for this delay. Future efforts 
should be directed toward ensuring fluid and efficient care transitions for patients with 
MIBC. The study also demonstrates that appropriate administration of NAC occurs in the 
community setting. Subsequent research should focus on the association between delay in 
cystectomy and survival outcomes in patients receiving NAC.
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Table 1
Patient characteristics of patients who received NAC in our AMC or in the community
Demographic Overall population (n = 47) NAC in community (n = 31) NAC in AMC (n = 16) P value
Age, median (range) 61 (31–86) 64 (31–86) 58 (36–74) 0.18
Male gender 34 (72.3%) 22 (71.0%) 12 (75.0%) 1.0
Race
 White 42 (89.4%) 29 (93.6%) 13 (81.3%) 0.17
 Black 4 (8.5%) 1 (3.2%) 3 (18.8%)
Smoking status
 Current 13 (27.7%) 10 (32.3%) 3 (18.8%) 0.46
 Former 28 (59.6%) 18 (58.1%) 10 (62.5%)
 Never 6 (12.8%) 3 (9.7%) 3 (18.8%)
BMI, kg/m2, median (range) 30 (15–43) 30 (19–43) 29 (15–38) 0.40
Marital status
 Married 30 (69.8%) 20 (71.4%) 10 (66.7%) 0.74
 Not married 13 (30.2%) 8 (28.6%) 5 (33.3%)
No insurance 3 (6.4%) 2 (6.5%) 1 (6.3%) 1.0
Age-adjusted CCI score, median (range) 5 (2–13) 5 (2–13) 3.5 (2–8) 0.17
Distance to AMC, miles (range) 83 (1–277) 130 (36–277) 58 (1–126) 0.0003
Stage at diagnosis
 2 36 (76.6%) 24 (77.4%) 12 (75%) 0.75
 3 4 (8.5%) 2 (6.5%) 2 (12.5%)
 4 7 (14.9%) 5 (16.1%) 2 (12.5%)
Preoperative creatinine, mg/dl median 
(range)
0.97 (0.58–1.55) 0.99 (0.59–1.55) 0.96 (0.58–1.41) 0.45
Histology
 Urothelial 45 (95.7%) 29 (93.5%) 16 (100%) 0.54
 Other 2 (4.3%) 2 (6.5%) 0 (0%)
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Table 2
Median number of days of delay in each step of process of receiving NAC in our AMC and in community 
setting
NAC in AMC NAC in community P value
Initial visit to starting NAC 11 21 0.002
Starting to ending NAC 64 68 0.33
Ending NAC to urology visit 24 30 0.48
Urology visit to cystectomy 32 37.5 0.18
Initial visit to cystectomy 128 162 0.006*
*
P =0.015 after adjusting for stage, comorbidity status, and distance to AMC.
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Table 3
Pathologic response rate at cystectomy and median dose of cisplatin received in those who received NAC in 
AMC vs. that in the community
NAC in AMC (n = 14) NAC in community (n =24) P value
pT0 at time of cystectomy 4 (28.6%) 6 (25.0%) 0.81
<pT2 at time of cystectomy 7 (50.0%) 12 (50.0%) 1.0
Median total dose of cisplatin received, mg/m2 280 280 0.82
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